I agree that this site is using cookies. You can find further informations here.
X
Yang, Shenmiao
49  results:
Search for persons X
?
1

The impact of Bruton's tyrosine kinase inhibitor treatment ..:

Yang, Shenmiao ; Wei, Rong ; Shi, Hongxia...
Frontiers in Oncology.  14 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
2

Zanubrutinib in patients with relapsed/refractory chronic l..:

Xu, Wei ; Yang, Shenmiao ; Zhou, Keshu...
Leukemia & Lymphoma.  64 (2023)  3 - p. 712-716 , 2023
Link: https://doi.org/10.1080/..
 
?
3

Orelabrutinib in relapsed or refractory chronic lymphocytic..:

Xu, Wei ; Zhou, Keshu ; Wang, Tingyu...
American Journal of Hematology.  98 (2023)  4 - p. 571-579 , 2023
Link: https://doi.org/10.1002/..
 
?
4

P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, ..:

LI, Caixia ; Wei, Jia ; Peng, Liu...
HemaSphere.  7 (2023)  S3 - p. e2710810 , 2023
Link: https://doi.org/10.1097/..
 
?
5

Impacts of early therapy response, interval to therapy inte..:

Yang, Shenmiao ; Li, Nan ; Zhu, Rong...
Annals of Hematology.  102 (2023)  8 - p. 2181-2188 , 2023
Link: https://doi.org/10.1007/..
 
?
6

P1555: COVID‑19 INFECTION IN PATIENTS WITH HEMATOLOGICAL MA..:

Zhu, Xiaolu ; Jiang, Qian ; Lu, Jin...
HemaSphere.  7 (2023)  S3 - p. e78808a9 , 2023
Link: https://doi.org/10.1097/..
 
?
7

COVID‐19 infection in patients with haematological malignan..:

Zhu, Xiaolu ; Jiang, Qian ; Lu, Jin...
British Journal of Haematology.  202 (2023)  1 - p. 31-39 , 2023
Link: https://doi.org/10.1111/..
 
?
8

Indirect comparisons of efficacy of zanubrutinib versus ore..:

Song, Yuqin ; Zhou, Keshu ; Yang, Shenmiao...
Investigational New Drugs.  41 (2023)  4 - p. 606-616 , 2023
Link: https://doi.org/10.1007/..
 
?
9

PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PAT..:

Yang, Shenmiao ; Huang, Haiwen ; Zhou, Keshu...
HemaSphere.  7 (2023)  S3 - p. e21928ec , 2023
Link: https://doi.org/10.1097/..
 
?
10

Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory ..:

Xu, Wei ; Yang, Shenmiao ; Tam, Constantine S....
Advances in Therapy.  39 (2022)  9 - p. 4250-4265 , 2022
Link: https://doi.org/10.1007/..
 
?
11

Efficacy and safety of GLS-010 (zimberelimab) in patients w..:

Lin, Ningjing ; Zhang, Mingzhi ; Bai, Hai...
European Journal of Cancer.  164 (2022)  - p. 117-126 , 2022
Link: https://doi.org/10.1016/..
 
?
12

Is unmeasurable residual disease (uMRD) the best surrogate ..:

Yang, Shenmiao ; Kay, Neil E. ; Shi, Min..
Leukemia.  36 (2022)  11 - p. 2743-2747 , 2022
Link: https://doi.org/10.1038/..
 
?
13

Cell therapy of chronic lymphocytic leukaemia: Transplants ..:

Yang, Shenmiao ; Huang, Xiaojun ; Gale, Robert Peter
Blood Reviews.  51 (2022)  - p. 100884 , 2022
Link: https://doi.org/10.1016/..
 
?
14

Bendamustine treatment of Chinese patients with relapsed in..:

Shi, Yuan-Kai ; Hong, Xiao-Nan ; Yang, Jian-Liang...
Chinese Medical Journal.  134 (2021)  11 - p. 1299-1309 , 2021
Link: https://doi.org/10.1097/..
 
?
15

Measurable residual disease testing in chronic lymphocytic ..:

Yang, Shenmiao ; Kay, Neil E. ; Shi, Min...
Leukemia.  35 (2021)  12 - p. 3364-3370 , 2021
Link: https://doi.org/10.1038/..
 
1-15